About
Aims
Frontiers in Translational Oncology and Molecular Therapeutics (FTOMT) is a peer-reviewed, open-access journal dedicated to the rapid dissemination of high-impact research that bridges the critical divide between laboratory-based molecular discoveries and clinical oncology practice. Our primary mission is to foster a multidisciplinary dialogue that accelerates the development of next-generation therapeutic strategies. We seek to provide a platform for studies that not only elucidate the underlying molecular pathways of oncogenesis but also demonstrate clear potential for clinical translation, including the improvement of patient stratification and treatment outcomes. By prioritizing the bench-to-bedside continuum, FTOMT aims to serve as a cornerstone for the oncology community in the era of precision medicine, ensuring that scientific breakthroughs are efficiently translated into tangible benefits for patients worldwide.
Scope
The journal welcomes submissions across the full spectrum of translational oncology, focusing on the intersection of molecular biology, pharmacology, and clinical practice. Specific areas of interest include, but are not limited to:
• Development and validation of novel targeted therapies, including small molecule inhibitors and next-generation biologics.
• Advanced drug delivery systems, specifically nanoparticle-mediated and ligand-targeted technologies designed to minimize systemic toxicity.
• The discovery and clinical utility of molecular biomarkers for early detection, prognosis, and treatment monitoring.
• Liquid biopsy technologies and their application in real-time monitoring of tumor evolution and minimal residual disease.
• Innovative gene and cell therapies, including CAR-T cell optimization and CRISPR-based therapeutic interventions.
• Molecular diagnostic tools that integrate multi-omics data (genomics, proteomics, and metabolomics) to inform clinical decision-making.
• Pharmacogenomic studies exploring the genetic basis of drug response and the mechanisms of acquired therapeutic resistance.
• Translational studies involving patient-derived xenografts (PDX), tumor organoids, and early-phase clinical trial results that provide mechanistic insights.
Article Types
To support a diverse range of scientific communication, FTOMT accepts the following article formats:
• Original Research: Full-length reports of primary experimental or clinical studies.
• Review Articles: Comprehensive syntheses of current literature and future directions in the field.
• Short Communications: Brief reports of high-impact preliminary findings that warrant rapid publication.
• Technical Notes: Detailed descriptions of innovative methodologies in molecular diagnostics or therapeutic delivery.
• Clinical Case Reports: Reports that highlight significant molecular insights or unique therapeutic responses in individual patients.
• Perspectives and Editorials: Expert commentary on emerging challenges and policy in translational medicine.
Audience
FTOMT is designed for an international audience of medical professionals and researchers. This includes clinical oncologists, molecular biologists, medicinal chemists, pharmacologists, and bioinformatics specialists. Furthermore, the journal serves as a vital resource for industry professionals in the biotechnology and pharmaceutical sectors who are focused on the commercial development of new drugs and diagnostic platforms.